We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$126M
Cap. Flow
+$65.1M
Cap. Flow %
3.43%
Top 10 Hldgs %
54.31%
Holding
63
New
4
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$17.3M
2
ITOS
iTeos Therapeutics
ITOS
+$16.4M
3
SYRE icon
Spyre Therapeutics
SYRE
+$15.1M
4
CGEM icon
Cullinan Oncology
CGEM
+$14M
5
REPL icon
Replimune Group
REPL
+$10.7M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$24.6M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
26
Immunovant
IMVT
$7.93B
$21.8M 1.15%
825,000
– –
KURA icon
27
Kura Oncology
KURA
$800M
$20.6M 1.08%
1,000,000
– –
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$18.7M 0.99%
1,590,000
– –
CLYM
29
Climb Bio
CLYM
$681M
$18.5M 0.97%
+2,603,190
New +$17.3M
DAWN
30
DELISTED
Day One Biopharmaceuticals
DAWN
$16.4M 0.86%
1,189,943
– –
SYRE icon
31
Spyre Therapeutics
SYRE
$8.54B
$16.4M 0.86%
696,480
+446,480
+179% +$15.1M
ARVN icon
32
Arvinas
ARVN
$518M
$16.2M 0.85%
608,614
– –
GPCR icon
33
Structure Therapeutics
GPCR
$3.41B
$15.7M 0.83%
400,000
– –
ELVN icon
34
Enliven Therapeutics
ELVN
$3.92B
$15.7M 0.83%
671,358
– –
PRTA icon
35
Prothena Corp
PRTA
$425M
$14.2M 0.75%
690,000
– –
REPL icon
36
Replimune Group
REPL
$941M
$13.8M 0.73%
+1,536,341
New +$10.7M
PSTX
37
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$13.1M 0.69%
4,475,000
– –
IPSC icon
38
Century Therapeutics
IPSC
$364M
$12.5M 0.66%
4,901,603
+3,151,603
+180% +$9.96M
ORIC icon
39
Oric Pharmaceuticals
ORIC
$1.15B
$12.2M 0.65%
1,732,571
– –
RLAY icon
40
Relay Therapeutics
RLAY
$4.1B
$11.9M 0.62%
1,819,132
– –
CGEM icon
41
Cullinan Oncology
CGEM
$1.01B
$11.5M 0.6%
+657,895
New +$14M
PRLD icon
42
Prelude Therapeutics
PRLD
$366M
$9.79M 0.52%
2,568,287
– –
ALLO icon
43
Allogene Therapeutics
ALLO
$649M
$8.97M 0.47%
3,850,000
– –
SANA icon
44
Sana Biotechnology
SANA
$871M
$8.44M 0.44%
1,545,000
– –
JSPR icon
45
Jasper Therapeutics
JSPR
$21M
$7.95M 0.42%
350,000
– –
OLMA icon
46
Olema Pharmaceuticals
OLMA
$1B
$7.03M 0.37%
+650,000
New +$7.05M
ENGN icon
47
enGene Therapeutics
ENGN
$120M
$6.86M 0.36%
727,900
– –
IOVA icon
48
Iovance Biotherapeutics
IOVA
$1.82B
$6.01M 0.32%
750,000
– –
AMLX icon
49
Amylyx Pharmaceuticals
AMLX
$2.26B
$2.85M 0.15%
1,500,000
– –
BOLD
50
Boundless Bio
BOLD
$56.2M
$2.75M 0.15%
711,329
– –
1
2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Boxer Capital held 63 positions worth $1.9B, down 6.2% from $2.02B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital deployed $65.1M of net new capital in Q2 2024, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Climb Bio: 2,603,190 shares worth $18.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the most notable exit was Viking Therapeutics, an estimated $24.6M sold.

  • Boxer Capital's largest Q2 2024 buy was Climb Bio: 2,603,190 shares worth $18.5M.
  • Boxer Capital added most to iTeos Therapeutics in Q2 2024, an estimated $16.4M increase.
  • Boxer Capital fully exited Viking Therapeutics in Q2 2024, selling an estimated $24.6M.
  • Boxer Capital's ten largest holdings make up 54% of its $1.9B portfolio in Q2 2024.
  • Boxer Capital opened 4 new positions and closed 2 in Q2 2024.
  • Boxer Capital's portfolio value fell 6.2% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q2 2024, filed 14 Aug 2024.